Limited coverage drugs – bimekizumab

Last updated on September 27, 2024

Generic name

bimekizumab

Strength

160 mg/mL
Form

solution for subcutaneous injection in a pre-filled syringe or pre-filled autoinjector

Special Authority criteria

Approval period

Treatment of moderate to severe plaque psoriasis, according to criteria detailed in form HLTH 5380: Biologics for Moderate to Severe Psoriasis (PDF, 781KB), when prescribed by a dermatologist First approval: 16 weeks

Renewal: 1 year

Practitioner exemptions

  • No practitioner exemptions

Special notes

  1. PharmaCare covers a maximum of 56 days per fill for bimekizumab (coverage limited to one 320 mg dose every 8 weeks at maintenance dosing)

Special Authority request form(s)